Why Eli Lilly Stock Just Dropped

MrDecoder · 2026-03-17T20:52:42+00:00

Eli Lilly's stock dropped 5% after HSBC downgraded it to "reduce," citing overly optimistic market predictions for GLP-1 weight-loss drugs. Analyst Rajesh Kumar forecasts lower revenue due to price competition and patient retention issues, raising concerns about the company's valuation amidst slowing growth expectations.

MrDecoder

2026-03-17 20:52:42

Abstract generation in progress

Eli Lilly (LLY 5.89%) stock tumbled 5% through noon ET Tuesday. You can blame investment bank HSBC for that.

HSBC, you see, just downgraded Lilly stock to sell.

Image source: Getty Images.

What HSBC just said about Eli Lilly stock

Well, technically, the word HSBC used was “reduce,” but it amounts to the same sentiment.

Most analysts forecast a total addressable market (TAM) for obesity drugs such as Novo Nordisk’s (NVO 0.28%) Ozempic, and Lilly’s Zepbound at over $150 billion. HSBC analyst Rajesh Kumar, however, thinks this number is optimistic. Looking as far out as 2032, he sees GLP-1 weight-loss drugs generating only $80 billion to $120 billion in annual revenue.

One problem with other analysts’ predictions is that, although GLP-1 drugs fetch rich prices, these prices are falling, and future “price competition is likely to be significant.” Another is that not all patients who start taking GLP-1 drugs will _continue _taking them, as shown by clinical trial discontinuation rates.

Already in 2025 and 2026, we’ve seen multiple rounds of price cuts between the two big GLP-1 companies. Lilly’s guidance suggests the company plans to make up the price cuts on volume, so to speak, to keep growth going – but Kumar isn’t convinced. (Nor am I.)

Expand

NYSE: LLY

Eli Lilly

Today’s Change

(-5.89%) $-58.31

Current Price

$930.81

Key Data Points

Market Cap

$935B

Day’s Range

$930.32 - $985.00

52wk Range

$623.78 - $1133.95

Volume

198K

Avg Vol

3.1M

Gross Margin

83.04%

Dividend Yield

0.63%

What this means for Eli Lilly investors

Priced at 43 times trailing earnings, and more than twice that when valued on free cash flow (Lilly claims net earnings much bigger than its actual cash profits), Eli Lilly’s valuation depends greatly on its growth rate. Analysts polled by S&P Global Market Intelligence, though, see earnings growing 22% or less annually over the next five years.

Even assuming that’s correct, the stock looks richly valued to me. If Kumar is right, Lilly stock could be even more expensive than it looks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.